BEFORE THE BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

In the Matter of the Accusation Against:

PCC VENTURES LLC,
dba PHARMACY CARE CONCEPTS
STEPHEN L. STANGE, PIC
HAROLD G. DELAMARTER, MEMBER
GREGORY JOHN VISLOCKY, MEMBER
RICK B. DELAMARTER, MD, MEMBER
SCOTT BRADLEY HANCOCK,
MEMBER
TRACY WILLIAM ZARLING, MEMBER
PAUL ERNEST HAFFNER, MEMBER
7720 Lorraine Avenue, Suite 102/103
Stockton, CA 95210

Original Pharmacy Permit No. PHY 51484

and

STEPHEN L. STANGE 4230 Heron Lakes Drive Stockton, CA 95219

Pharmacist License No. RPH 28242

Respondents.

Case No. 5294

OAH No. 2015110440

STIPULATED SETTLEMENT AND DISCIPLINARY ORDER AS TO RESPONDENT STEPHEN L. STANGE ONLY

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order is here by adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on June 6, 2016.

It is so ORDERED on May 5, 2016.

BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA

By

Amy Gutierrez, Pharm.D. Board President

1	KAMALA D. HARRIS Attorney General of California				
2	JANICE K. LACHMAN Supervising Deputy Attorney General				
3	KRISTINA T. JARVIS				
4	Deputy Attorney General State Bar No. 258229				
5	1300 I Street, Suite 125 P.O. Box 944255				
6	Sacramento, CA 94244-2550 Telephone: (916) 324-5403				
7	Facsimile: (916) 327-8643 Attorneys for Complainant				
8	BEFORE THE				
9	BOARD OF PHARMACY DEPARTMENT OF CONSUMER AFFAIRS				
10	STATE OF CALIFORNIA				
11	In the Matter of the Accusation Against:	Case No. 5294			
12	PCC VENTURES LLC, dba PHARMACY CARE CONCEPTS	OAH No. 2015110440			
13	STEPHEN L. STANGE, PIC	STIPULATED SETTLEMENT AND			
14	HAROLD G. DELAMARTER, MEMBER GREGORY JOHN VISLOCKY, MEMBER RICK B. DELAMARTER, MD, MEMBER	DISCIPLINARY ORDER AS TO RESPONDENT STEPHEN L. STANGE			
15	SCOTT BRADLEY HANĆOCK,	ONLY			
16	MEMBER TRACY WILLIAM ZARLING, MEMBER				
17	PAUL ERNEST HAFFNER, MEMBER 7720 Lorraine Avenue, Suite 102/103				
18	Stockton, CA 95210	·			
19	Original Pharmacy Permit No. PHY 51484	·			
20	and				
21	-STEPHEN-L. STANGE 4230 Heron Lakes Drive	· · · · · · · · · · · · · · · · · · ·			
22	Stockton, CA 95219				
23	Pharmacist License No. RPH 28242				
24	Respondents.				
25					
26	IT IS HEREBY STIPULATED AND AGE	REED by and between the parties to the above-			
27	entitled proceedings that the following matters are true:				
28	///				
		1			
		STIPLILATED SETTLEMENT (5204)			

PARTIES

- 1. Virginia Herold ("Complainant") is the Executive Officer of the Board of Pharmacy. She brought this action solely in her official capacity and is represented in this matter by Kamala D. Harris, Attorney General of the State of California, by Kristina T. Jarvis, Deputy Attorney General.
- 2. On or about March 14, 2001, the Board issued Original Pharmacy Permit Number PHY 45169 to Pharmacy Care Concepts, Inc., with Stephen L. Stange ("Respondent Stange") as pharmacist-in-charge ("PIC") and president/treasurer. The pharmacy permit was canceled on July 2, 2013, due to a change in ownership of the pharmacy, as set forth in paragraph 3 below.
- 3. On or about July 1, 2013, the Board issued Original Pharmacy Permit Number PHY 51484 to PCC Ventures LLC ("Respondent PCC" or "PCC"), doing business as Pharmacy Care Concepts, with Respondent Stange as PIC and Harold G. Delamarter, Gregory John Vislocky, Rick B. Delamarter, MD, Scott Bradley Hancock, Tracy William Zarling, and Paul Ernest Haffner as members. The pharmacy permit was in full force and effect at all times relevant to the charges brought herein and will expire on July 1, 2016, unless renewed.
- 4. On or about April 24, 1973, the Board issued Pharmacist License Number RPH 28242 Respondent Stange. The pharmacist license was in full force and effect at all times relevant to the charges brought herein and will expire on August 31, 2017, unless renewed.
- 5. Respondent PCC is represented in this proceeding by attorney Ivan Petrzelka, whose address is: 2855 Michelle Drive, Suite 180. Irvine, CA 92606.
- 6. Respondent Stange is represented in this proceeding by attorney Gregory P. Matzen, whose address is: 2104 Big Sandy Court, Gold River, CA 95670.

JURISDICTION

7. Accusation No. 5294 was filed before the Board of Pharmacy (Board), Department of Consumer Affairs, and is currently pending against Respondents. The Accusation and all other statutorily required documents were properly served on Respondents on September 24, 2015. Respondent timely filed their Notices of Defense contesting the Accusation.

8. A copy of Accusation No. 5294 is attached as exhibit A and incorporated herein by reference.

ADVISEMENT AND WAIVERS

- 9. Respondent Stange has carefully read, fully discussed with counsel, and understands the charges and allegations in Accusation No. 5294. Respondent Stange has also carefully read, fully discussed with counsel, and understands the effects of this Stipulated Settlement and Disciplinary Order.
- 10. Respondent Stange is fully aware of his legal rights in this matter, including the right to a hearing on the charges and allegations in the Accusation; the right to be represented by counsel at his own expense; the right to confront and cross-examine the witnesses against him; the right to present evidence and to testify on his own behalf; the right to the issuance of subpoenas to compel the attendance of witnesses and the production of documents; the right to reconsideration and court review of an adverse decision; and all other rights accorded by the California Administrative Procedure Act and other applicable laws.
- 11. Respondent Stange voluntarily, knowingly, and intelligently waives and gives up each and every right set forth above.

CULPABILITY

- 12. Respondent Stange understands that the charges and allegations in Accusation No. 5294, if proven at hearing constitute cause for imposing discipline upon his Pharmacy License.
- 13. For the purposes of resolving the Accusation without the expense and uncertainty of further proceedings, Respondent Stange agrees that, at a hearing, Complainant could establish a factual basis for the charges in the Accusation and that those charges constitute cause for discipline. Respondent Stange hereby gives up their right to contest that cause for discipline exists based on those charges and agrees to be bound by the Board's Decision and Order.
- 14. Respondent Stange understands that by signing this stipulation he enables the Board to issue an order revoking his Pharmacist License and placing it on probation subject to the terms and conditions set forth in the Disciplinary Order below.

 \parallel / \parallel

 $\frac{20}{21}$

CONTINGENCY

- Stange understands and agrees that counsel for Complainant and the staff of the Board of Pharmacy may communicate directly with the Board regarding this stipulation and settlement, without notice to or participation by Respondent Stange or his counsel. By signing the stipulation, Respondent Stange understands and agrees that he may not withdraw his agreement or seek to rescind the stipulation prior to the time the Board considers and acts upon it. If the Board fails to adopt this stipulation as its Decision and Order, the Stipulated Settlement and Disciplinary Order shall be of no force or effect, except for this paragraph, it shall be inadmissible in any legal action between the parties, and the Board shall not be disqualified from further action by having considered this matter.
- 16. The parties understand and agree that Portable Document Format (PDF) and facsimile copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile signatures thereto, shall have the same force and effect as the originals.
- 17. This Stipulated Settlement and Disciplinary Order is intended by the parties to be an integrated writing representing the complete, final, and exclusive embodiment of their agreement. It supersedes any and all prior or contemporaneous agreements, understandings, discussions, negotiations, and commitments (written or oral). This Stipulated Settlement and Disciplinary Order may not be altered, amended, modified, supplemented, or otherwise changed except by a writing executed by an authorized representative of each of the parties.
- 18. If there is any violation of probation for which a petition to revoke probation is filed by the Board, then all of the charges and allegations in Accusation No. 5294 shall be deemed to be true, correct, and admitted for the purpose of that proceeding.
- 19. In consideration of the foregoing admissions and stipulations, the parties agree that the Board may, without further notice or formal proceeding, issue and enter the following Disciplinary Order:

DISCIPLINARY ORDER

IT IS HEREBY ORDERED that Pharmacist License No. RPH 28242 issued to Respondent

Stephen L. Stange is revoked. However, the revocation is stayed and Respondent is placed on probation for five (5) years on the following terms and conditions.

1. Obey All Laws

Respondent Stange shall obey all state and federal laws and regulations.

Respondent Stange shall report any of the following occurrences to the board, in writing, within seventy-two (72) hours of such occurrence:

- an arrest or issuance of a criminal complaint for violation of any provision of the
 Pharmacy Law, state and federal food and drug laws, or state and federal controlled substances laws
- a plea of guilty or nolo contendre in any state or federal criminal proceeding to any criminal complaint, information or indictment
- a conviction of any crime
- discipline, citation, or other administrative action filed by any state or federal agency which involves respondent's pharmacist license or which is related to the practice of pharmacy or the manufacturing, obtaining, handling, distributing, billing, or charging for any drug, device or controlled substance.

Failure to timely report such occurrence shall be considered a violation of probation.

2. Report to the Board

Respondent Stange shall report to the board quarterly, on a schedule as directed by the board or its designee. The report shall be made either in person or in writing, as directed. Among other requirements, respondent shall state in each report under penalty of perjury whether there has been compliance with all the terms and conditions of probation. Failure to submit timely reports in a form as directed shall be considered a violation of probation. Any period(s) of delinquency in submission of reports as directed may be added to the total period of probation. Moreover, if the final probation report is not made as directed, probation shall be automatically extended until such time as the final report is made and accepted by the board.

28 | ///

 $/\!/\!/$

3. Interview with the Board

Upon receipt of reasonable prior notice, respondent Stange shall appear in person for interviews with the board or its designee, at such intervals and locations as are determined by the board or its designee. Failure to appear for any scheduled interview without prior notification to board staff, or failure to appear for two (2) or more scheduled interviews with the board or its designee during the period of probation, shall be considered a violation of probation.

4. Cooperate with Board Staff

Respondent Stange shall cooperate with the board's inspection program and with the board's monitoring and investigation of respondent's compliance with the terms and conditions of his probation. Failure to cooperate shall be considered a violation of probation.

5. Continuing Education

Respondent Stange shall provide evidence of efforts to maintain skill and knowledge as a pharmacist as directed by the board or its designee.

6. Notice to Employers

During the period of probation, respondent Stange shall notify all present and prospective employers of the decision in case number 5294 and the terms, conditions and restrictions imposed on respondent by the decision, as follows:

Within thirty (30) days of the effective date of this decision, and within fifteen (15) days of respondent undertaking any new employment, respondent shall cause his direct supervisor, pharmacist-in-charge (including each new pharmacist-in-charge employed during respondent's tenure of employment) and owner to report to the board in writing acknowledging that the listed individual(s) has/have read the decision in case number 5294, and terms and conditions imposed thereby. It shall be respondent's responsibility to ensure that his employer(s) and/or supervisor(s) submit timely acknowledgment(s) to the board.

If respondent works for or is employed by or through a pharmacy employment service, respondent must notify his direct supervisor, pharmacist-in-charge, and owner at every entity licensed by the board of the terms and conditions of the decision in case number 5294 in advance

of the respondent commencing work at each licensed entity. A record of this notification must be provided to the board upon request.

Furthermore, within thirty (30) days of the effective date of this decision, and within fifteen (15) days of respondent undertaking any new employment by or through a pharmacy employment service, respondent shall cause his direct supervisor with the pharmacy employment service to report to the board in writing acknowledging that he has read the decision in case number 5294 and the terms and conditions imposed thereby. It shall be respondent's responsibility to ensure that his employer(s) and/or supervisor(s) submit timely acknowledgment(s) to the board.

Failure to timely notify present or prospective employer(s) or to cause that/those employer(s) to submit timely acknowledgments to the board shall be considered a violation of probation.

"Employment" within the meaning of this provision shall include any full-time, part-time, temporary, relief or pharmacy management service as a pharmacist or any position for which a pharmacist license is a requirement or criterion for employment, whether the respondent is an employee, independent contractor or volunteer.

7. No Supervision of Interns, Serving as Pharmacist-in-Charge (PIC), Serving as Designated Representative-in-Charge, or Serving as a Consultant

During the period of probation, respondent Stange shall not supervise any intern pharmacist, be the pharmacist-in-charge or designated representative-in-charge of any entity licensed by the board nor serve as a consultant unless otherwise specified in this order.

Assumption of any such unauthorized supervision responsibilities shall be considered a violation

Assumption of any such unauthorized supervision responsibilities shall be considered a violation of probation.

8. Reimbursement of Board Costs

As a condition precedent to successful completion of probation, respondent shall pay to the board its costs of investigation and prosecution in the amount of \$5,368.25. Respondent shall make said payments in a payment plan approved by the Board in writing.

27 || -

28 || 4

There shall be no deviation from this schedule absent prior written approval by the board or its designee. Failure to pay costs by the deadline(s) as directed shall be considered a violation of probation.

The filing of bankruptcy by respondent shall not relieve respondent of his responsibility to reimburse the board its costs of investigation and prosecution.

9. Probation Monitoring Costs

Respondent Stange shall pay any costs associated with probation monitoring as determined by the board each and every year of probation. Such costs shall be payable to the board on a schedule as directed by the board or its designee. Failure to pay such costs by the deadline(s) as directed shall be considered a violation of probation.

10. Status of License

Respondent Stange shall, at all times while on probation, maintain an active, current license with the board, including any period during which suspension or probation is tolled. Failure to maintain an active, current license shall be considered a violation of probation.

If respondent's license expires or is cancelled by operation of law or otherwise at any time during the period of probation, including any extensions thereof due to tolling or otherwise, upon renewal or reapplication respondent's license shall be subject to all terms and conditions of this probation not previously satisfied.

11. License Surrender While on Probation/Suspension

Following the effective date of this decision, should respondent cease practice due to retirement or health, or be otherwise unable to satisfy the terms and conditions of probation, respondent may tender his license to the board for surrender. The board or its designee shall have the discretion whether to grant the request for surrender or take any other action it deems appropriate and reasonable. Upon formal acceptance of the surrender of the license, respondent will no longer be subject to the terms and conditions of probation. This surrender constitutes a record of discipline and shall become a part of the respondent's license history with the board.

Upon acceptance of the surrender, respondent shall relinquish his pocket and wall license to the board within ten (10) days of notification by the board that the surrender is accepted.

Respondent may not reapply for any license from the board for three (3) years from the effective date of the surrender. Respondent shall meet all requirements applicable to the license sought as of the date the application for that license is submitted to the board, including any outstanding costs.

12. Notification of a Change in Name, Residence Address, Mailing Address or Employment

Respondent Stange shall notify the board in writing within ten (10) days of any change of employment. Said notification shall include the reasons for leaving, the address of the new employer, the name of the supervisor and owner, and the work schedule if known. Respondent Stange shall further notify the board in writing within ten (10) days of a change in name, residence address, mailing address, or phone number.

Failure to timely notify the board of any change in employer(s), name(s), address(es), or phone number(s) shall be considered a violation of probation.

13. Tolling of Probation

Except during periods of suspension, respondent Stange shall, at all times while on probation, be employed as a pharmacist in California for a minimum of 40 hours per calendar month. Any month during which this minimum is not met shall toll the period of probation, i.e., the period of probation shall be extended by one month for each month during which this minimum is not met. During any such period of tolling of probation, respondent must nonetheless comply with all terms and conditions of probation.

Should respondent, regardless of residency, for any reason (including vacation) cease practicing as a pharmacist for a minimum of 40 hours per calendar month in California, respondent must notify the board in writing within ten (10) days of the cessation of practice, and must further notify the board in writing within ten (10) days of the resumption of practice. Any failure to provide such notification(s) shall be considered a violation of probation.

It is a violation of probation for respondent's probation to remain tolled pursuant to the provisions of this condition for a total period, counting consecutive and non-consecutive months, exceeding thirty-six (36) months.

"Cessation of practice" means any calendar month during which respondent is not practicing as a pharmacist for at least 40 hours, as defined by Business and Professions Code section 4000 et seq. "Resumption of practice" means any calendar month during which respondent is practicing as a pharmacist for at least 40 hours as a pharmacist as defined by Business and Professions Code section 4000 et seq.

Respondent is required to practice as a pharmacist in a licensed pharmacy setting that dispenses medication for a minimum of one year prior to the completion of probation. After the first year of probation, the board or its designee may consider a modification of this requirement. If respondent fails to comply with this requirement or a subsequent modification thereto, such failure shall be considered a violation of probation.

14. Violation of Probation

If a respondent has not complied with any term or condition of probation, the board shall have continuing jurisdiction over respondent, and probation shall automatically be extended, until all terms and conditions have been satisfied or the board has taken other action as deemed appropriate to treat the failure to comply as a violation of probation, to terminate probation, and to impose the penalty that was stayed.

If respondent violates probation in any respect, the board, after giving respondent notice and an opportunity to be heard, may revoke probation and carry out the disciplinary order that was stayed. Notice and opportunity to be heard are not required for those provisions stating that a violation thereof may lead to automatic termination of the stay and/or revocation of the license. If a petition to revoke probation or an accusation is filed against respondent during probation, the board shall have continuing jurisdiction and the period of probation shall be automatically extended until the petition to revoke probation or accusation is heard and decided.

15. Completion of Probation

Upon written notice by the board or its designee indicating successful completion of probation, respondent's license will be fully restored.

16. Community Services Program

Within sixty (60) days of the effective date of this decision, respondent Stange shall submit

21

22

23

24

25

26

27

28

to the board or its designee, for prior approval, a community service program in which respondent shall perform community service for at least 150 hours during the period of probation. At least 50% of these community service hours must be free health-care related services on a regular basis to a community or charitable facility or agency. Within thirty (30) days of board approval thereof, respondent shall submit documentation to the board demonstrating commencement of the community service program. A record of this notification must be provided to the board upon request. Respondent shall report on progress with the community service program in the quarterly reports. Failure to timely submit, commence, or comply with the program shall be considered a violation of probation.

Remedial Education 17.

Within sixty (60) days of the effective date of this decision, respondent shall submit to the board or its designee, for prior approval, an appropriate program of remedial education related to prescription drug abuse, pharmacy security, pharmacy operations, and appropriate policies and procedures. The program of remedial education shall consist of at least six (6) hours every year of probation for a total of thirty (30) hours over the five year period at respondent's own expense. At least 50% of the thirty (30) hours, a minimum of fifteen (15) hours, must be live, in-person continuing education. All remedial education shall be in addition to, and shall not be credited toward, continuing education (CE) courses used for license renewal purposes.

Failure to timely submit or complete the approved remedial education shall be considered a violation of probation. The period of probation will be automatically extended until such remedial education is successfully completed and written proof, in a form acceptable to the board, is provided to the board or its designee.

Following the completion of each course, the board or its designee may require the respondent, at his own expense, to take an approved examination to test the respondent's knowledge of the course. If the respondent does not achieve a passing score on the examination, this failure shall be considered a violation of probation. Any such examination failure shall require respondent to take another course approved by the board in the same subject area.

///

18. No Ownership of Licensed Premises

Respondent shall not own, have any legal or beneficial interest in, or serve as a manager, administrator, member, officer, director, trustee, associate, or partner of any business, firm, partnership, or corporation currently or hereinafter licensed by the board. Respondent shall sell or transfer any legal or beneficial interest in any entity licensed by the board within ninety (90) days following the effective date of this decision and shall immediately thereafter provide written proof thereof to the board. Failure to timely divest any legal or beneficial interest(s) or provide documentation thereof shall be considered a violation of probation.

ACCEPTANCE

I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully discussed it with my attorney, Gregory P. Matzen. I understand the stipulation and the effect it will have on my Pharmacist License. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Board of Pharmacy.

DATED: <u>1/23/16</u>

STEPHEN L. STANGE

Respondent

APPROVAL AS TO FORM AND CONTENT

I have read and fully discussed with Respondent PCC Ventures, LLC dba Pharmacy Care Concepts; Stephen L. Stange, Pharmacist-in-Charge the terms and conditions and other matters contained-in-the above-Stipulated-Settlement-and-Disciplinary-Order, I approve its-form-and-

content.

DATED: 2/29//

Gregory P. Matzen (Andrney for Respondent

İ

///

| ///

ENDORSEMENT The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Board of Pharmacy. Dated: February 26, 2016 Respectfully submitted, KAMALA D. HARRIS Attorney General of California JANICE K. LACHMAN Supervising Deputy Attorney General Deputy Attorney General Attorneys for Complainant SA2014117593 12125893.docx

STIPULATED SETTLEMENT (5294)

Exhibit A

Accusation No. 5294

1 2 3 4	KAMALA D. HARRIS Attorney General of California JANICE K. LACHMAN Supervising Deputy Attorney General KRISTINA T. JARVIS Deputy Attorney General State Bar No. 258229 1300 I Street, Suite 125 P.O. Box 944255 Sacramento, CA 94244-2550 Telephone: (916) 324-5403			
3	JANICE K. LACHMAN Supervising Deputy Attorney General KRISTINA T. JARVIS Deputy Attorney General State Bar No. 258229 1300 I Street, Suite 125 P.O. Box 944255 Sacramento, CA 94244-2550 Telephone: (916) 324-5403			
	Supervising Deputy Attorney General KRISTINA T. JARVIS Deputy Attorney General State Bar No. 258229 1300 I Street, Suite 125 P.O. Box 944255 Sacramento, CA 94244-2550 Telephone: (916) 324-5403			
	Deputy Attorney General State Bar No. 258229 1300 I Street, Suite 125 P.O. Box 944255 Sacramento, CA 94244-2550 Telephone: (916) 324-5403	;		
4]	1300 I Street, Suite 125 P.O. Box 944255 Sacramento, CA 94244-2550 Telephone: (916) 324-5403	;		
	P.O. Box 944255 Sacramento, CA 94244-2550 Telephone: (916) 324-5403	;		
5	Telephone: (916) 324-5403			
6				
7	Facsimile: (916) 327-8643 Attorneys for Complainant			
8	BEFOR	RE THE		
9		PHARMACY ONSUMER AFFAIRS		
	STATE OF C			
10		1		
11	In the Matter of the Accusation Against:	Case No. 5294		
12	PCC VENTURES LLC, dba PHARMACY CARE CONCEPTS			
13	STEPHEN L. STANGE, PIC	ACCUSATION		
14	HAROLD G. DELAMARTER, MEMBER GREGORY JOHN VISLOCKY, MEMBER			
15	RICK B. DELAMARTER, MD, MEMBER SCOTT BRADLEY HANCOCK, MEMBER			
16	TRACY WILLIAM ZARLING, MEMBER PAUL ERNEST HAFFNER, MEMBER			
17	7720 Lorraine Avenue, Suite 102/103 Stockton, CA 95210			
18	Original Pharmacy Permit No. PHY 51484			
19	·			
ļ	and	·		
20	STEPHEN L. STANGE 4230 Heron Lakes Drive			
-2:1-	Stockton, CA 95219			
22	Pharmacist License No. RPH 28242			
23	Respondents.			
24				
25	Complainant alleges:			
26	PARTIES/LICENS	E INFORMATION		
27	1. Virginia Herold ("Complainant") bri	1. Virginia Herold ("Complainant") brings this Accusation solely in her official capacity		
28	as the Executive Officer of the Board of Pharmac	cy ("Board"), Department of Consumer Affairs.		
		1		

Accusation

7. Code section 4300.1 states:

The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license.

8. Code section 4301 states, in pertinent part:

The board shall take action against any holder of a license who is guilty of unprofessional conduct or whose license has been procured by fraud or misrepresentation or issued by mistake. Unprofessional conduct shall include, but is not limited to, any of the following:

(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or by any other state or federal regulatory agency

9. Code section 4032 states that "[I]icense means and includes any license, permit, registration, certificate, or exemption issued by the board and includes the process of applying for and renewing the same."

10. Code section 4022 states:

"Dangerous drug" or "dangerous device" means any drug or device unsafe for self-use in humans or animals, and includes the following:

- (a) Any drug that bears the legend: "Caution: federal law prohibits dispensing without prescription," "Rx only," or words of similar import.
- this device to sale by or on the order of a ———," "Rx only," or words of similar import, the blank to be filled in with the designation of the practitioner licensed to use or order use of the device.
- (c) Any other drug or device that by federal or state law can be lawfully dispensed only on prescription or furnished pursuant to Section 4006.
- 11. Code section 4063 states, in pertinent part, that "[n]o prescription for any dangerous drug or dangerous device may be refilled except upon authorization of the prescriber. The authorization may be given orally or at the time of giving the original prescription . . ."

| ///

- 12. Code section 4105, subdivision (a), states that "[a]ll records or other documentation of the acquisition and disposition of dangerous drugs and dangerous devices by any entity licensed by the board shall be retained on the licensed premises in a readily retrievable form."
- 13. Code section 4113, subdivision (c), states that "[t]he pharmacist-in-charge shall be responsible for a pharmacy's compliance with all state and federal laws and regulations pertaining to the practice of pharmacy.
- 14. California Code of Regulations, title 16, section ("Regulation") 1714, subdivision (d), states:

Each pharmacist while on duty shall be responsible for the security of the prescription department, including provisions for effective control against theft or diversion of dangerous drugs and devices, and records for such drugs and devices. Possession of a key to the pharmacy where dangerous drugs and controlled substances are stored shall be restricted to a pharmacist.

COST RECOVERY

15. Code section 125.3 provides, in pertinent part, that a Board may request the administrative law judge to direct a licentiate found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

CONTROLLED SUBSTANCES/DANGEROUS DRUGS

- 16. "Norco", "Lortab", and "Vicodin ES" are compounds consisting of varying quantities of acetaminophen and hydrocodone bitartrate, also known as dihydrocodeinone, and are Schedule III controlled substances as designated by Health and Safety Code section 11056, subdivision (e)(4). Norco, Lortab, and Vicodin ES are used to relieve moderate to severe pain.
- 17. "Percocet" is a compound consisting of oxycodone and acetaminophen, and is a Schedule II controlled substance as designated by Health and Safety Code section 11055, subdivision (b)(1)(M). Percocet is used to relieve moderate to severe pain.
- 18. "Methadose", a brand of methadone hydrochloride, is a Schedule II controlled substance as designated by Health and Safety Code section 11055, subdivision (c)(14). Methadose is used to treat opioid addiction as well as relieve severe pain.

III

2.7

21₋

- 19. "Concerta", a brand of methylphenidate, is a Schedule II controlled substance as designated by Health and Safety Code section 11055, subdivision (d)(6). Concerta is used to treat attention deficit hyperactivity disorder (ADHD).
- 20. "Fentanyl" is a Schedule II controlled substance as designated by Health and Safety Code section 11055, subdivision (c)(8). Fentanyl is used as part of anesthesia to help prevent pain after surgery or other medical procedure.
- 21. "Adderall XR" is a compound consisting of mixed salts of dextroamphetamine and/or amphetamine, and is a Schedule II controlled substance as designated by Health and Safety Code section 11055, subdivision (d)(1). Adderall XR is indicated for the treatment of ADHD.
- 22. The above controlled substances are dangerous drugs within the meaning of Code section 4022 in that they require a prescription under federal law.

BACKGROUND

- 23. On or about November 6, 2013, the Board received a report from PIC Stange, notifying them that an unlicensed staff member, M. M., may have obtained 960 tablets of Norco 10/325 mg from the pharmacy without a valid prescription. PIC Stange stated that on or about June 10, 2013, a legal prescription was obtained from a physician's assistant for M. M.'s husband, J. M., for 240 tablets of Norco 10/325 mg, with zero refills. On August 2, 2013, M. M. presented a photocopy of the prescription to the billing technician, who processed it, and the prescription was then filled by pharmacy technician C. L. M. M. took the prescription before it was reviewed by a pharmacist.
- 24. PIC Stange also stated that on August 29, 2013, September 14, 2013, and October 2, 2013, M. M. presented C. L. with prescription labels "from the initial dispensing date (August 2, 2013)." C. L. filled the prescriptions (240 tablets of Norco 10/325 mg in each instance) after M. M. "promised" that she had a valid refill for each label. It appeared that M. M. took each of the prescriptions before final review by a pharmacist.
- 25. PIC Stange listed various corrective actions the pharmacy had taken since the incident, including filing a police report with the Stockton Police Department and suspending

2-1

///

///

///

M. M. from her employment on October 12, 2013 (M. M. subsequently resigned on October 14, 2013).

- 26. On or about November 14, 2013, the Board sent a letter to PIC Stange, requesting certain information and documents pertaining to the reported theft/loss of controlled substances.
- 27. On or about December 19, 2013, the Board received various documents from PIC Stange, including a Drug Enforcement Agency (DEA) Form 106 dated October 16, 2013. PCC reported a loss of controlled substances valued at \$2,000, including 14,706 tablets of hydrocodone/acetaminophen 10/325; the type of theft/loss was listed as "Employee Pilferage". PIC Stange also provided the Board with a statement, indicating that the business was sold to PCC on June 27, 2013, and that he and the new owner, pharmacist Scott Hancock ("Hancock"), conducted an inventory or audit of Schedule 2 medications and hydrocodone-related products, which "reflected a much larger problem than previously discovered." PIC Stange submitted a copy of the audit; it was conducted for the time period from June 28, 2013 to November 26, 2013. PIC Stange indicated in an additional statement that the audit was based on an inventory from June 27, 2013 to November 26, 2013, purchase records from various wholesalers, including Valley Wholesale and HD Smith (Smart Source), prescription utilization reports, and reverse distributor reports.
- 28. On or about January 17, 2014, PIC Stange submitted additional documents to the Board, including a letter dated January 10, 2014. PIC Stange stated that since the reported loss of controlled substances following the sale of PCC was significant, he and Hancock conducted another audit-for a time-period-prior to the sale, specifically, from January 18, 2013 (the date the last biennial inventory was completed at PPC prior to the sale) to June 27, 2013 (the date of sale). This audit revealed significant losses as well, as set forth below. PIC Stange also provided DEA Form 106 dated January 14, 2014, showing that the losses applied to Pharmacy Care Concepts,

21-

Inc. PIC Stange stated in an additional statement to the Board that the audit was based on inventory records from January 18, 2013 to June 26, 2013, purchase records from wholesalers Valley Wholesale and HD Smith, prescription utilization reports, and reverse distributor reports.

Drug and Strength	Quantity Reported Loss (Units) for Audit Period from 01/18/2013 – 11/26/2013
hydrocodone/acetaminophen 10/325 mg	20,601
hydrocodone/acetaminophen 10/500 mg	489
hydrocodone/acetaminophen 7.5/325 mg	2,230
hydrocodone/acetaminophen 7.5/500 mg	705
hydrocodone/acetaminophen 7.5/750 mg	3,604
hydrocodone/acetaminophen 5/325 mg	850
hydrocodone/acetaminophen 5/500 mg	1,192
Fentanyl 12 mcg patch	17
Mixed amphetamine salts ER 20 mg	90

- 29. On or about March 4, 2014, Board Inspector C. H. conducted an inspection and investigation at the pharmacy.
- 30. C. H. asked PIC Stange if they ever found the original prescription. PIC Stange told C. H. that they only had a copy. C. H. asked PIC Stange why the prescription was filled when only a copy of the original prescription was presented. PIC Stange stated that he thought M. M. may have exploited the normal workflow for long-term care facilities.
- 31. PIC Stange explained that for some controlled substance prescriptions, the board and care facility had the original order from the patient or the patient's family. The care facility normally faxed a copy of the original prescription to PCC so the order could be prepared for the patient and delivered the same day. The fax copy of the prescription was sent through the workflow in order-to-get-it-filled, and the medication-was then placed in a bin for delivery the same day. Once the medication was delivered, the original prescription was picked up and brought to the pharmacy that day. The pharmacist would sign the original prescription as well as the faxed copy, indicating final review of the prescription. The clerk or technician would keep a second copy of the prescription at their workstation as a reminder to follow up with the pharmacist and driver to ensure the original prescription was brought to the pharmacy. The only copy the pharmacy had of the prescription was the one found next to clerk S. The copy had not

been signed by a pharmacist. PIC Stange told C. H. he verified with the physician's assistant that the prescription was valid and that there were no refills authorized.

- 32. C. H. obtained various documents from the pharmacy, including a copy of the original prescription and copies of pharmacy labels confirming that the prescription was processed as RX# 1326725 on August 2, 2013, with no refills. C. H. also obtained a controlled substances inventory log, purchase records from June 28, 2013 to November 26, 2013, from Smart Source, Cardinal, and Valley Wholesale, and drug usage reports from June 28, 2013 to November 26, 2013, for each controlled substance included in the audit.
- 33. On or about May 30, 2014, C. H. sent HD Smith and Valley Wholesaler requests for copies of records of purchases, sales, returns, and credits for certain products sold to or purchased from PCC for the time period from June 28, 2013 through November 26, 2013.
- 34. On or about June 2, 2014, C. H. received copies of purchase records from HD Smith. C. H. found that the purchase record data corresponded to the data from PCC's audit.
- 35. On or about June 5, 2014, C. H. received copies of purchase records from Valley Wholesaler. C. H. reviewed the purchase data twice for accuracy and compared it to the purchase data reported in PCC's audit. C. H. found no discrepancies.
- 36. On or about June 20, 2014, C. H. used the documents she received from PCC, including the inventory records, purchase records, and dispensing records, to verify their audit results for all drugs which showed a significant loss, as well as oxycodone IR (all strengths), methadone 5 mg, methylphenidate 36 mg, and oxycodone/acetaminophen 5/325 mg and 10/325. C. H. found no discrepancies. C. H. then used the purchase records-she-received-from-HD Smithand Valley Wholesaler to independently verify selected PCC audit entries for the

23 | ///

24 | ///

25 | ///

26 | ///

27 | ///

28 | ///

3

4 5

6

8

9

10

11 12

13

14 15

16 17

18 19

20 21

22 23

24 25

26

27 28 hydrocodone/acetaminophen products with a significant loss. C. H. found no discrepancies. The audit conducted by PCC revealed the following losses as verified by C. H.:

Drug and Strength	Reported Loss (Units) for Audit Period from 06/28/2013 – 11/26/2013	% of Acquisition
hydrocodone/acetaminophen 10/325 mg	14,706	34.2
hydrocodone/acetaminophen 10/500 mg	204	40.8
hydrocodone/acetaminophen 7.5/325 mg	911	13.6
hydrocodone/acetaminophen 7.5/500 mg	614.5	61.4
hydrocodone/acetaminophen 7.5/750 mg	751	150
oxycodone/acetaminophen 10/325 mg	141	3.8
methadone 5 mg	100_	8.3
methylphenidate 36 mg	30	33

CAUSE FOR DISCIPLINE

(Violations of the Pharmacy Law and State

Laws and Regulations Governing Pharmacy)

- Respondents PCC and Stange are subject to disciplinary action pursuant to Code section 4301, subdivision (o), for unprofessional conduct, in that Respondents violated or attempted to violate, directly or indirectly, assisted in or abetted the violation of, or conspired to violate provisions or terms of the Pharmacy Law (Bus. & Prof. Code § 4300, et seq.) and state laws and regulations governing pharmacy, as follows:
- On or about August 29, 2013, September 14, 2013, and October 2, 2013, Respondents PCC and Stange authorized or permitted pharmacy technician C. L. to dispense refills of RX# 1326725, for 240 tablets of the controlled substance hydrocodone/acetaminophen 10/325 mg, for patient J. M. when, in fact, the physician's assistant-who issued the original prescription had not authorized any refills, in violation of Code section 4063.
- Respondents PCC and Stange failed to maintain on their premises and/or have available for inspection by Board inspector C. H. the original prescription for RX# 1326725 issued for patient J. M., as set forth in paragraphs 30 and 31 above, in violation of Code section 4105.
- On and between June 28, 2013 and November 26, 2013, Respondents PCC and Stange failed to maintain or ensure the security of the prescription department and/or include

provisions for effective control against theft or diversion of dangerous drugs and devices, resulting in a significant loss of controlled substances, as set forth in paragraph 36 above, in violation of Regulation 1714, subdivision (d).

On and between January 18, 2013 and June 27, 2013, Respondent Stange failed to maintain or ensure the security of the prescription department and/or include provisions for effective control against theft or diversion of dangerous drugs and devices, resulting in a significant loss of controlled substances, as set forth in paragraph 28 above, in violation of Regulation 1714, subdivision (d).

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

- Revoking or suspending Pharmacy Permit Number PHY 51484, issued to PCC Ventures LLC, doing business as Pharmacy Care Concepts;
- 2. Revoking or suspending Pharmacist License Number RPH 28242, issued to Stephen L. Stange;
- 3. Ordering PCC Ventures LLC, doing business as Pharmacy Care Concepts, and Stephen L. Stange to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3;
 - 4. Taking such other and further action as deemed necessary and proper.

Executive Officer Board of Pharmacy

Department of Consumer Affairs

State of California

Complainant

SA2014117593